Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

ENDEAVOR: carfilzomib new standard in multiple myeloma?

Dr Keith Stewart - Mayo Clinic, Rochester, USA

ENDEAVOR: carfilzomib new standard in multiple myeloma? ( Dr Keith Stewart - Mayo Clinic, Rochester, USA )

How can functional drug screening guide personalised cancer therapy?

Prof Jeff Tyner - Oregon Health & Science University, Portland, USA

How can functional drug screening guide personalised cancer therapy? ( Prof Jeff Tyner - Oregon Health & Science University, Portland, USA )

Combining treatment options for higher risk myelodysplastic syndromes and...

Dr Mikkael Sekeres - Cleveland Clinic Foundation, Cleveland, USA

Combining treatment options for higher risk myelodysplastic syndromes and chronic myelomonocytic leukaemia ( Dr Mikkael Sekeres - Cleveland Clinic Foundation, Cleveland, USA )

Incidence of and predictors for early death in paediatric patients with acute...

Dr Oussama Abla - The Hospital for Sick Children, Toronto, Canada

Incidence of and predictors for early death in paediatric patients with acute promyelocytic leukaemia ( Dr Oussama Abla - The Hospital for Sick Children, Toronto, Canada )

Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic...

Prof Giovanni Martinelli - University of Bologna, Bologna, Italy

Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype ( Prof Giovanni Martinelli - University of Bologna, Bologna, Italy )

Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia

Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France

Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia ( Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France )

First all-oral treatment for relapsed and treatment-resistant multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France

First all-oral treatment for relapsed and treatment-resistant multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )

Experimental oral therapy for high-risk CLL shows promise

Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany

Experimental oral therapy for high-risk CLL shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia

Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )

ASH 2015: New targeted therapies for haematological malignancies

Dr Robert Hromas - University of Florida, Gainesville, USA

ASH 2015: New targeted therapies for haematological malignancies ( Dr Robert Hromas - University of Florida, Gainesville, USA )

Exciting new immunosuppressive therapy treatment for aplastic anaemia

Dr Danielle Townsley - George Washington University School of Medicine...

Exciting new immunosuppressive therapy treatment for aplastic anaemia ( Dr Danielle Townsley - George Washington University School of Medicine, Washington, USA )

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia...

Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )

More from ecancer